Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEAN pediatric Behçet oral ulcers trial
NL-OMON54968Phase 3Withdrawn
- Sponsor
- Amgen
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Behçet's disease (BD) comparing Apremilast then apremilast with Placebo then apremilast (2 arms). Planned start Feb 2021; status: withdrawn.
02
Drugs
apremilast
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on NL-OMON54968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54968.